This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Charalambous, C. Articles by Hofman, F. M. Search for Related Content PubMed PubMed Citation Articles by Charalambous, C. Articles by Hofman, F. M.

Interleukin-8 Differentially Regulates Migration of Tumor-Associated and Normal Human Brain Endothelial Cells

Departments of ¹ Molecular Microbiology and Immunology, ² Pathology, and ³ Neurosurgery, University of Southern California Keck School of Medicine, Los Angeles, California; and ⁴ Department of Cell Biology and Neuroscience, University of California at Riverside, Riverside, California

Requests for reprints: Florence M. Hofman, Department of Pathology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033. Phone: 323-442-1150; Fax: 323-442-3049; E-mail: hofman{at}usc.edu.

Interleukin-8 (IL-8) is a chemokine involved in angiogenesis, a process vital to tumor growth. Previously, we showed that endothelial cells derived from human tumor tissue have different functional and phenotypic properties compared with normal endothelial cells. This study analyzes the role of IL-8 in regulating angiogenesis of tumor-associated brain endothelial cells (TuBEC). Results show that TuBECs have a higher baseline migration rate compared with normal brain endothelial cells (BEC). TuBECs are unaffected when stimulated with IL-8 whereas BECs are activated. This lack of response of TuBECs to IL-8 is due to the constitutive production of IL-8. Endogenously produced IL-8 activates TuBECs in an autocrine manner as shown by IL-8 receptor inhibition. Blocking either CXCR1 or CXCR2 partially reduces TuBEC migration, whereas blocking both receptors further reduces migration. Treatment with antibody against vascular endothelial growth factor (VEGF) shows that production of IL-8 by TuBECs is dependent on VEGF. Transforming growth factor-ß1 (TGF-ß1), shown to down-regulate IL-8 production in BECs, does not inhibit IL-8 production in TuBECs. In summary, these studies show that TuBECs constitutively secrete IL-8 and autocrine activation by IL-8 is the result of VEGF stimulation. Furthermore, TuBECs do not respond to the feedback inhibition normally induced by TGF-ß1. These data emphasize the functional uniqueness of TuBECs. Understanding the functions and regulatory processes of tumor-associated endothelial cells is critical for developing appropriate antiangiogenic therapies.

This article has been cited by other articles:

				J. J. Virrey, S. Guan, W. Li, A. H. Schonthal, T. C. Chen, and F. M. Hofman Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells Am. J. Pathol., August 1, 2008; 173(2): 575 - 585. [Abstract] [Full Text] [PDF]

				C. Rolny, L. Capparuccia, A. Casazza, M. Mazzone, A. Vallario, A. Cignetti, E. Medico, P. Carmeliet, P. M. Comoglio, and L. Tamagnone The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment J. Exp. Med., May 12, 2008; 205(5): 1155 - 1171. [Abstract] [Full Text] [PDF]

				N. D. Gross, J. O. Boyle, B. Du, V. D. Kekatpure, A. Lantowski, H. T. Thaler, B. B. Weksler, K. Subbaramaiah, and A. J. Dannenberg Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5910 - 5917. [Abstract] [Full Text] [PDF]

				S. Araki, Y. Omori, D. Lyn, R. K. Singh, D. M. Meinbach, Y. Sandman, V. B. Lokeshwar, and B. L. Lokeshwar Interleukin-8 Is a Molecular Determinant of Androgen Independence and Progression in Prostate Cancer Cancer Res., July 15, 2007; 67(14): 6854 - 6862. [Abstract] [Full Text] [PDF]

				L. S. Angelo and R. Kurzrock Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators Clin. Cancer Res., May 15, 2007; 13(10): 2825 - 2830. [Abstract] [Full Text] [PDF]